Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized study of intranasal IRO-203 booster vaccination in COVID-19 vaccinated adults
jRCT2031230116Phase 1Completed
- Sponsor
- DNAVEC
- Start
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IRO-203 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by DNAVEC. Primary endpoint: Safety and tolerability. Started Jun 2023; status: completed.
02
Drugs
IRO-203
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230116.